Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Xospata

- PMLiVE

Advagraf shows survival increase for liver transplant patients

Astellas drug shows significant improvement in study published in the AJT

- PMLiVE

England’s medicine prices ‘too high’

New analysis finds NICE is too lenient on pharma’s price tags

National Institute for Health and Care Excellence NICE logo

NICE sets out approach to stop antimicrobial resistance

Guidelines call for formation of stewardship programmes

- PMLiVE

NICE issues fresh rejection for Celgene’s cancer drug Imnovid

Drugpricing watchdog says the treatment is too costly for NHS use

- PMLiVE

Astellas joins trial data sharing website

Joins Bayer, Boehringer, GSK, Lilly, Novartis, Roche and more

- PMLiVE

NICE consults on reducing melanoma cases

New guidance set to focus on diagnosing and managing the skin cancer  

- PMLiVE

NICE backs first ‘ultra-orphan’ drug Soliris

Final guidance backs Alexion’s treatment for very rare blood clot condition

- PMLiVE

FDA panel backs new antifungal Cresemba

Basilea/Astellas drug tipped to become a $500m product

- PMLiVE

NICE heart attack recommendation for Xarelto

Bayer drug on course for another blood clot indication in England and Wales

- PMLiVE

CDF chair regrets undermining NICE

But Prof Clark says he wholeheartedly supports the Institute

- PMLiVE

Eric Terhaerdt leaves AZ for Astellas

Joins as senior VP of global development operations

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links